These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32462248)

  • 41. Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials.
    Zhang X; Chen L; Zhao Y; Yin H; Ma H; He M
    Biomed Res Int; 2019; 2019():9283860. PubMed ID: 31950058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
    Allen PB; Gordon LI
    Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
    Zhang YC; Wang JN; Ma SY; Cai J; Su N; Huang HQ; Li ZM; Xia ZJ; Huang H; Liu PP; Xia Y; Cai QQ
    Br J Haematol; 2022 Jan; 196(1):127-135. PubMed ID: 34618912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune checkpoint inhibition in classical hodgkin lymphoma.
    Pezeshki PS; Eskian M; Hamblin MR; Rezaei N
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1003-1016. PubMed ID: 33857395
    [No Abstract]   [Full Text] [Related]  

  • 54. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
    Issa AK; Westin JR
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):483-487. PubMed ID: 27364263
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
    Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
    BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.
    Manson G; Herbaux C; Brice P; Bouabdallah K; Stamatoullas A; Schiano JM; Ghesquieres H; Dercle L; Houot R;
    Blood; 2018 Jun; 131(25):2856-2859. PubMed ID: 29724901
    [No Abstract]   [Full Text] [Related]  

  • 59. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.
    Wang Y; Nowakowski GS; Wang ML; Ansell SM
    J Hematol Oncol; 2018 Apr; 11(1):57. PubMed ID: 29685160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
    Bair SM; Mato A; Svoboda J
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.